Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.

Daijiro Harada Tomoki TamuraKiichiro NinomiyaToshio KuboShoichi KuyamaSayaka TachibanaKoji InoueKenichi ChikamoriKenichiro KudoNobuaki OchiYoshinobu MaedaKatsuyuki Kiura

Published in: Thoracic cancer (2022)

Anti-SARS-CoV-2 mRNA vaccination is safe; however, post-vaccination fever is more common in patients undergoing lung cancer treatment than in healthy individuals.

Keyphrases

sars cov
patients undergoing
patient reported outcomes
respiratory syndrome coronavirus
cross sectional
locally advanced
clinical trial
binding protein
coronavirus disease
rectal cancer
chemotherapy induced